乳腺癌患者外周血中hMAM、SBEM和CEACAM19 mRNA联合检测及其临床意义  

Combined detection of hMAM,SBEM and CEACAM19 mRNA in peripheral blood of breast cancer patients and its clinical significance

作　　者：于秀艳[1] 李铤[1] 丛占杰 王文龙[1] 张晓伟[1] 吴雪峰[1] YU Xiuyan;LI Ting;CONG Zhanjie;WANG Wenlong;ZHANG Xiaowei;WU Xuefeng(Department of Clinical Laboratory,Jilin Provincial Tumor Hospital,Changchun 130012,China)

机构地区：[1]吉林省肿瘤医院检验科,吉林长春130012

出　　处：《吉林大学学报（医学版）》2022年第1期195-202,共8页Journal of Jilin University：Medicine Edition

基　　金：吉林省卫计委卫生与健康技术创新项目(2018J025)。

摘　　要：目的:探讨外周血中人乳腺珠蛋白(hMAM)、乳腺小黏蛋白(SBEM)和癌胚抗原相关黏附因子19(CEACAM19)mRNA联合检测在乳腺癌诊断中的作用,阐明其临床意义。方法:收集104例乳腺癌患者(乳腺癌组)、52例乳腺良性病变患者(良性乳腺病组)和50名健康人(健康对照组)的外周血,采用实时荧光定量PCR(RT-qPCR)法检测受试者外周血有核细胞中hMAM、SBEM和CEACAM19 mRAN表达水平并计算其阳性表达率,分析其与乳腺癌患者临床病理特征的关系。结果:乳腺癌组患者外周血中SBEM和CEACAM19 mRNA阳性表达率与淋巴结转移有关联(P<0.05),CEACAM19 mRNA阳性表达率与雌激素受体(ER)表达有关(P<0.05),hMAM mRNA阳性表达率与人表皮生长因子受体2(HER-2)表达有关(P<0.05)。与健康对照组和良性乳腺病组比较,乳腺癌组患者外周血中hMAM单独或联合SBEM和CEACAM19 mRNA检测阳性表达率均明显升高(P<0.05)。三者联合检测,hMAMmRNA阳性表达率从39.4%升高至66.3%。TNM分期Ⅲ+Ⅳ期乳腺癌患者外周血中hMAM单独或联合SBEM和(或)CEACAM19 mRNA检测阳性表达率均高于TNM分期Ⅰ+Ⅱ期乳腺癌患者(P<0.01);三者联合检测,TNM分期Ⅰ+Ⅱ期乳腺癌患者外周血中hMAMmRNA阳性表达率从20.40%升高至48.98%,TNM分期Ⅲ+Ⅳ期乳腺癌患者外周血中hMAMmRNA阳性表达率从56.40%升高至81.82%。结论:乳腺癌患者外周血hMAMmRNA阳性表达率不高,联合SBEM和CEACAM19 mRNA检测可以提高其阳性表达率,对于乳腺癌诊断具有一定的临床意义。Objective:To investigate the effect of combined detection of the biomarkers human mammaglobin(hMAM),small breast epithelial mucin(SBEM) and carcino-embryonic antigen related adhesion molecule 19(CEACAM19)mRNA in the diagnosis of breast cancer,and to clarify its clinical significance. Methods:The peripheral blood was collected from 104 breast cancer patients(breast cancer group),52 benign breast disease patients(benign breast disease group)and 50 healthy individuals(healthy control group),and the expression levels of hMAM,SBEM and CEACAM19 mRAN in peripheral blood nucleated cells were detected by real-time fluorescence quantitative PCR(RT-qPCR)method;the positive expression rates were calculated and their relationships with patients’ clinicopathologic features were analyzed. Results:In breast cancer group,the positive expression rates of SBEM and CEACAM19 mRNA in peripheral blood were associated with lymph node metastasis(P<0. 05),the positive expression rate of CEACAM19 mRNA was associated with estrogen receptor(ER)expression(P<0. 05),and the positive expression rate of hMAM mRNA was associated with human epidermal growth factor receptor-2(HER-2)expression(P<0. 05). The positive expression rates of hMAM mRNA in peripheral blood in breast cancer group were significantly increased compared with healthy control group and benign breast disease group(P<0. 05),both alone and in combined with SBEM and CEACAM19. The positive expression rate of hMAM mRNA was increased from 39. 4% to 66. 3% by combined detection of the three indicators. The positive expression rates of hMAM mRNA in peripheral blood of the breast cancer patients at TNM stage Ⅲ+Ⅳ were higher than those of patients at TNM stage Ⅰ+Ⅱ(P<0. 01),both alone and in combined with SBEM and CEACAM19. By combined detection of hMAM,SBEM,andCEACAM19 mRNA,the positive expression rate of hMAM mRNA in peripheral blood of the breast cancer patients at TNM stage Ⅰ + Ⅱ was increased from 20. 40% to 48. 98% and at TNM stage Ⅲ + Ⅳ from 56. 40% to 81. 82%. Conclu

关 键 词：乳腺肿瘤 微转移 人乳腺珠蛋白 乳腺上皮小黏蛋白 癌胚抗原相关黏附因子19 

分 类 号：R730.43[医药卫生—肿瘤] R737.9[医药卫生—临床医学]